Each year, in honor of World Cancer Day, the Bonnie J. Addario Lung Cancer Foundation (ALCF) launches a unique, international crowdsourcing challenge that leverages the power of the crowd to solve problems plaguing the oncology clinical medicine space.
For 2016 World Cancer Day, we want YOU to join us and #BeTheSolution!
On February 4, 2016 we launched the second phase of the Clinical Trial Innovation Prize, a unique, two-part, $180,000 crowdsourcing challenge that seeks to identify innovative ways to increase cancer patient enrollment in clinical trials.
Goal: The goal of the challenge is to produce breakthroughs that will increase the patient accrual rate to oncology clinical trials.
Phases and Winners
Cancer is one of the leading causes of death worldwide, with the number of new cases expected to rise by approximately 70% over the next two decades.
We need better ways to prevent, detect, screen and treat cancer patients, and we need them now!
The most reliable and the only accepted scientific method to take discoveries from the lab bench to the bedside is testing the safety and efficacy of these new interventions in clinical trials — research studies that test new methods of prevention, detection, screening and treatment of cancer.
The U.S. National Institutes of Health database currently lists over 45,000 cancer-related clinical trials worldwide.
Unfortunately, more than 20% of these trials will never complete, for reasons unrelated to the effectiveness of the intervention that’s being tested! That is a huge drain on the already very limited research $$ and resources, will delay clinical research and getting useful diagnostics and treatments to cancer patients.
The most common reason for 20% of all clinical trials never finishing is poor patient accrual (the process of recruiting patients to the trial for participation), i.e. not enough patients volunteered to join the clinical trial.
On average, less than 3-5% of all adult cancer patients participate in clinical trials!
Participation is even lower among particular groups, including people who are racial and ethnic minorities, over 65, lower income, and living in rural areas. As an example, ~53% of new cancer diagnoses are in people 65 or older, however, this age demographic accounts for a measly 33% of clinical trial participants
Some of the most common reasons for poor patient accrual to cancer clinical trials include:
Why an Innovation Prize?
We know that amazing ideas can come from anywhere. Despite 50 years of trying, members of the medical community have been unable to develop transformational solutions to these intractable problems.
So, we are trying something different! We want you to help us find cool ways to increase the accrual rate of cancer clinical trials!
We believe an Innovation Prize could have a profound impact on improving cancer care, too.
Help us make it happen!
The Challenge Breakthrough
The Clinical Trial Innovation Prize is looking for innovative means to increase the number of cancer patients participating in clinical trials, increasing the accrual rates for cancer clinical trials from the current 3-5%.
Increased participation in clinical trials will hopefully accelerate the pace of research and drug development allowing patients to live longer and better lives.
We are looking:
The Clinical Trial Innovation Prize will award a total of $180,000 in prizes.
These prizes will be awarded in two phases as follows:
Our panel of judges will select first and second prize winners for the Implementation Phase, based on the judging criteria listed below.
Please register here to participate. Applications may be submitted either individually or by teams of innovators. There are no restrictions on age, country of origin, gender, educational accomplishments, etc. We are looking for brilliant, out-of-the-box thinkers and innovators to help us solve the problem of patient accrual to oncology clinical trials.
The Implementation Phase of the Clinical Trials Innovation Prize has two rounds:
All applicants who wish to participate in the $150,000 Implementation Phase of the Challenge need to submit a two-page proposal describing their solution, the specific barriers it addresses and how these will be overcome (details at herox.com/clinicaltrials).
All submissions will be evaluated by our panel of judges and a total of 25 applicants will proceed into the Proof-of-Concept round of the challenge.
Top 12 finalists from the first phase or Ideation phase of the challenge, and 13 new applicants will be selected to enter the Proof-of-Concept round of the Clinical Trials Innovation Prize.
The Proof-of-Concept round of the Implementation Challenge will run for 6 months during which all 25 teams will be mentored by the Addario Lung Cancer Foundation, as well as our mentoring committees of key experts in the clinical trials space. ALCF will provide all 25 teams access to any resources they might need to test and implement their ideas to increase patient accrual to clinical trials.
At the end of six months, all 25 teams will have to submit the following:
The Judging Panel comprises of thought leaders in the business, academic and non profit worlds. Judges will evaluate all submissions on compliance with the rules and guidelines of the Prize, and will have the sole and absolute discretion to select the winners. The Judging Panel’s decisions are final, binding and are not subject to challenge.
All Judges will be required to sign and adhere to non-disclosure agreements as required and statements acknowledging that they make no claim to the Intellectual Property developed by teams.
All submissions will be evaluated on the following weighted criteria:
|Scalability and Sustainability||
|Analysis of Obstacles||
Challenge rules are subject to change. All registered teams and individuals will be informed of any rule changes and any changes will be posted on the Challenge page.
Click here to submit an entry. All Ideation Challenge submissions will be made public upon submission to allow for an exchange of ideas, as well as allowing innovators to fine-tune their submissions based on feedback they get from the crowd.
You can make changes to your entry until the final submission deadline on May 18, 2015, 9pm EST (extended from May 6, 2015). No changes can be made to submissions after this time.
Your challenge submission remains your own. By participating in this challenge, each competitor agrees to submit only their own idea. Any indication of “copying” another competitors’ idea is grounds for disqualification from the challenge.
People’s Choice Award selected by a Public Vote
The Judging Panel will select a group of finalists to be eligible for the People’s Choice Award. The finalist receiving the most votes will be awarded the People’s Choice Award. A competitor is eligible to win both a Judges’ Award and the People’s Choice Award. All votes will be monitored and any indication of impropriety will result in disqualification from the challenge.
Have questions? Send us an email at [email protected], and we’ll get back to you right away!
If you have a solution that you believe could increase accrual rates but don’t know how to implement it, email us. We will support you to determine how best to test the solution.
We know the next breakthrough can come from anywhere and
we are committed to finding a way to increase patient accrual to clinical trials!